DongKook Pharmaceutical Co. Ltd (086450) — Cash Flow-to-Debt Ratio
DongKook Pharmaceutical Co. Ltd (086450) has a Cash Flow-to-Debt Ratio of 0.07x as of March 2026, meaning its operating cash flow of ₩22.58 Billion could theoretically repay 0% of its total liabilities (₩310.75 Billion) in one year. See how financially flexible is DongKook Pharmaceutical Co. Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DongKook Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for DongKook Pharmaceutical Co. Ltd across 13 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of DongKook Pharmaceutical Co. Ltd.
Annual Cash Flow-to-Debt Ratio for DongKook Pharmaceutical Co. Ltd (2013–2025)
Year-by-year debt coverage analysis for DongKook Pharmaceutical Co. Ltd. Check 086450 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | ₩68.76 Billion | ₩299.16 Billion | ▼ -17.2% |
| 2024 | 0.28x | ₩76.09 Billion | ₩274.19 Billion | ▲ +74.9% |
| 2023 | 0.16x | ₩41.79 Billion | ₩263.36 Billion | ▲ +3.3% |
| 2022 | 0.15x | ₩40.91 Billion | ₩266.39 Billion | ▲ +1.6% |
| 2021 | 0.15x | ₩44.65 Billion | ₩295.51 Billion | ▼ -35.6% |
| 2020 | 0.23x | ₩59.11 Billion | ₩251.80 Billion | ▼ -38.7% |
| 2019 | 0.38x | ₩69.48 Billion | ₩181.51 Billion | ▲ +92.8% |
| 2018 | 0.20x | ₩33.21 Billion | ₩167.22 Billion | ▼ -24.2% |
| 2017 | 0.26x | ₩28.66 Billion | ₩109.37 Billion | ▼ -41.6% |
| 2016 | 0.45x | ₩39.41 Billion | ₩87.78 Billion | ▲ +24.4% |
| 2015 | 0.36x | ₩27.14 Billion | ₩75.18 Billion | ▲ +7.3% |
| 2014 | 0.34x | ₩22.74 Billion | ₩67.60 Billion | ▼ -5.1% |
| 2013 | 0.35x | ₩19.86 Billion | ₩56.02 Billion | — |